New observational data suggest SGLT2 inhibitor initiation may improve kidney and survival outcomes in a higher-risk group defined by gout plus type 2 diabetes. A multicenter retrospective cohort study reported that starting SGLT2 inhibitors was associated with lower risk of incident chronic kidney disease and all-cause mortality among adults with gout and type 2 diabetes. The findings add to accumulating real-world evidence supporting SGLT2 inhibitors beyond standard glycemic effects, particularly in patients with overlapping inflammatory and metabolic risk factors. For clinicians and payers, the result strengthens the rationale for earlier SGLT2 inhibitor use where gout is present—while still implying the need for prospective confirmation given the retrospective design.
Get the Daily Brief